BETA DRUGS LIMITED Fair Value
BETA · Healthcare · Current price ₹2,229.1
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹317 | 19% ROE fading to 13% over ~10 yrs, on ₹241 book |
| Relative P/E | ₹1,600 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹471 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is BETA DRUGS LIMITED undervalued?
DocStoX estimates the fair value of BETA DRUGS LIMITED at ₹702 per share, versus the current market price of ₹2,229. That puts the stock about -68.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹317), Relative P/E (₹1,600), Graham floor (₹471). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹317 (bear) to ₹702 (base) to ₹1,600 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on BETA DRUGS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.